retatrutide phase 2 nejm 2023 percent weight loss 48 weeks Results: 24% in Retatrutide: A Triple Agonist Shaping

There were no hepatotoxicity signals in the overall obesity trial population or in the subset of participants with MASLD through 48 weeks

Despite its efficacy in glycemic control and weight reduction, several factors prompt patients to consider discontinuation

Importantly, no significant adverse effects on linear growth, pubertal development, or bone health were observed during treatment periods [179]

This can lead to significant weight loss in the first few weeks of the diet but it tends to level out after that Plus, much of early weight loss is water because carbohydrates store water

Bariatric surgery, behavioral therapy, and dulaglutide did not help her quiet the food noise or lose weight

[DOI] [PMC free article] [PubMed] [Google Scholar] 86.Meurot C, et al